M1 Kliniken AG: Supervisory Board adopts (consolidated) financial statements 2021 of M1 Kliniken AG. No deviations from the preliminary figures for financial year 2021 published at the end of March

DGAP-News: M1 Kliniken AG / Key word(s): Annual Results
M1 Kliniken AG: Supervisory Board adopts (consolidated) financial statements 2021 of M1 Kliniken AG. No deviations from the preliminary figures for financial year 2021 published at the end of March
04.05.2022 / 09:00
The issuer is solely responsible for the content of this announcement.

Supervisory Board of M1 Kliniken AG adopts (consolidated) financial statements 2021 of M1 Kliniken AG. No deviations from the preliminary figures for financial year 2021 published at the end of March

- Supervisory Board adopts the 2021 annual financial statements of M1 Kliniken AG, which have been audited with unqualified audit opinions

- Turnover almost doubles to almost 315 million euros. Group operating result (EBIT) almost tripled to €12.1 million (€4.4 million in 2020)

- The Supervisory Board and the Executive Board propose to the Annual General Meeting that the balance sheet profit be carried forward in full to new account. Investments in sustainable growth planned.

Berlin, 4 May 2022 - At its meeting yesterday, the Supervisory Board of M1 Kliniken AG adopted the annual financial statements of M1 Kliniken AG (separate financial statements according to HGB and consolidated financial statements according to IFRS), which were issued with unqualified audit opinions. The preliminary figures already communicated at the end of March 2022 were confirmed in full.
M1 Kliniken AG's consolidated revenue rose to a total of € 314 million in financial year 2021, compared with just under € 160 million in the previous year. The operating result almost tripled to € 12.1 million (2021) after € 4.4 million in 2020.

In the future, the M1 Group will continue to focus clearly on growth and the development of new market segments. For example, Haemato AG is increasingly concentrating on the product business and the implementation of a clinical study for the European approval of its own Botox product in cooperation with Huons Bioharma from South Korea. M1 will push the expansion of the practice network in Germany and internationally with the goal of developing the number of operating locations towards 100 in the next three years. Against this background and in order to secure the financing of growth, the Supervisory Board and the Executive Board decided in its meeting today to propose to the Annual General Meeting that the balance sheet profit be carried forward in full to new account.

The Annual Report 2021 of M1 Kliniken AG will be published on 19 May 2022.

About M1 Kliniken AG
M1 Kliniken AG is the leading provider of beauty medical health services in Germany. In the aesthetic and surgical field, the group of companies offers products and services with the highest quality standards. Under the brand "M1 Med Beauty", beauty medical treatments are currently offered at more than 50 specialist centres. The M1 Schlossklinik for plastic and aesthetic surgery in Berlin, with six operating theatres and 35 beds, is one of the largest and most modern facilities of its kind in Europe. Since the end of 2018, M1 has been pushing ahead with internationalisation and is currently also active in Austria, Switzerland, the Netherlands, England, Croatia and Australia. With its stake in HAEMATO AG, M1 Kliniken AG is also in a position to exploit sales and earnings potential of treatment products in the medical-aesthetic field.

04.05.2022 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de